SCHEMBL1147526

SCHEMBL1147526

CCN(CC)CCC(=O)N(CCCCCN)c1ccnc2cc(Cl)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPT P10636 1/20 0.46
NSD1 Q96L73 1/20 0.46
KCNH2 Q12809 5/20 0.46
CYP2D6 P10635 4/20 0.46
CHRM2 P08172 3/20 0.46
CHRM1 P11229 3/20 0.46
ADRA2C P18825 3/20 0.46
NR4A2 P43354 3/20 0.46
CYP2C19 P33261 3/20 0.46
CHRM4 P08173 2/20 0.46
CHRM5 P08912 2/20 0.46
ADRA2A P08913 2/20 0.46
ADRA2B P18089 2/20 0.46
CHRM3 P20309 2/20 0.46
TMEM97 Q5BJF2 2/20 0.46
SIGMAR1 Q99720 2/20 0.46
ACE2 Q9BYF1 2/20 0.46
APP P05067 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1147384 1.00 KDM4E (0.46) KDM4EHSD17B10MAPTNSD1KCNH2
SCHEMBL1147575 0.99 KDM4E (0.47) KDM4EHSD17B10MAPTNSD1KCNH2
SCHEMBL1147375 0.96 KDM4E (0.48) KDM4EHSD17B10MAPTNSD1KCNH2
SCHEMBL1147303 0.92 LMNA (0.49) KDM4EHSD17B10MAPTNSD1KCNH2
SCHEMBL1550998 0.83 KDM4E (0.58) KDM4EHSD17B10MAPTNSD1KCNH2
SCHEMBL1147508 0.81 CHRM2 (0.53) KDM4EHSD17B10MAPTNSD1KCNH2
SCHEMBL1147605 0.81 CHRM2 (0.53) KDM4EHSD17B10MAPTNSD1KCNH2
SCHEMBL1147504 0.80 NR4A2 (0.54) KDM4EHSD17B10MAPTNSD1KCNH2
SCHEMBL1550687 0.78 CDK1 (0.62) KDM4EHSD17B10MAPTNSD1KCNH2
SCHEMBL1146976 0.77 NR4A2 (0.55) KDM4EHSD17B10MAPTNSD1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110045100-A1 Antimalarial Quinolines and Methods of Use Thereof GEORGETOWN UNIVERSITY (US) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110045100-A1 Antimalarial Quinolines and Methods of Use Thereof NQO2, QTRT1, QTRT2 KDM4E 1366/4885HSD17B10 3428/4885MAPT 2777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.